Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30601900 | 1.00 | TDP1 (0.58) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL997571 | 1.00 | TDP1 (0.58) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL8072364 | 1.00 | TDP1 (0.58) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL29545568 | 1.00 | TDP1 (0.58) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL31036100 | 1.00 | TDP1 (0.58) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL793609 | 1.00 | TDP1 (0.58) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL6505837 | 0.98 | TDP1 (0.56) | TDP1L3MBTL1CYP1A2CYP2C19HDAC8 | |
| SCHEMBL571198 | 0.93 | CASP3 (0.54) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL12134369 | 0.87 | HEXA (0.66) | MEN1KMT2AHDAC8HDAC3HDAC4 | |
| SCHEMBL12134377 | 0.87 | HEXA (0.66) | MEN1KMT2AHDAC8HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-3340981-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-4053117-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114044800-A | Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders | 艾其林医药公司 | 2022-02-15 | — | — | CN | disclosed |
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-2688921-B1 | DIBLOCK COPOLYMERS PREPARED BY CROSS METATHESIS | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180305375-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-10-25 | — | — | US | disclosed |
| EP-0817643-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1997036480-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1996030036-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0662834-A4 | NOVEL EPOXIDE-CONTAINING COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0697873-A4 | — | — | 1996-04-03 | — | — | EP | disclosed |
| EP-0697873-A1 | OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1996-02-28 | — | — | EP | disclosed |
| WO-1995026722-A1 | METHOD FOR INHIBITING MAST CELL AND BASOPHIL ACTIVATION | CELL THERAPEUTICS, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
| EP-0662834-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994015606-A1 | OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994006431-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | TDP1 3304/4885L3MBTL1 4258/4885CHRM2 2731/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | TDP1 3248/4885L3MBTL1 4256/4885CHRM2 2752/4885 |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | TDP1 3304/4885L3MBTL1 4258/4885CHRM2 2731/4885 |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | TDP1 3304/4885L3MBTL1 4258/4885CHRM2 2731/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | TDP1 3304/4885L3MBTL1 4258/4885CHRM2 2731/4885 |
| US-20180305375-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | TDP1 3304/4885L3MBTL1 4258/4885CHRM2 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.